US · PLSM · MEDICAL - DEVICES
Pulsenmore Ltd. Ordinary Shares (PLSM) intrinsic value and stock valuation
$1.29as of 2026-11-21 · Mkt cap 23.02M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pulsenmore Ltd. Ordinary Shares DCF and intrinsic value
InvestorsCraft values PLSM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PLSM’s statements →
Pulsenmore Ltd. Ordinary Shares Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40M | $9.64M | $6.14M | $10.6M | $1.58M |
| Operating income | -$-12.16M | -$-42.12M | -$-55.11M | -$-45.25M | -$-21.92M |
| Net income | -$-15.85M | -$-36.65M | -$-58.07M | -$-21.66M | -$-25.61M |
| EPSd | -$-2.47M | -$-5.73M | -$-9.07M | -$-3.59M | -$-4.99M |
| Operating cash flow | -$-32.88M | -$-33.71M | -$-42.45M | -$-24.51M | -$-26.01M |
| Capital expenditure | -$-140K | -$-510K | -$-3.89M | -$-4.41M | -$-770K |
| Free cash flow | -$-33.01M | -$-34.22M | -$-46.34M | -$-28.92M | -$-26.79M |
| Total assets | $101.9M | $141.5M | $178.4M | $231.5M | $167M |
| Total debt | $1.56M | $3.23M | $5.69M | $6.92M | $1.02M |
| Net debt | -$-20.04M | -$-37.98M | -$-18.12M | -$-8.27M | -$-111.9M |
| Total equity | $83.1M | $96.7M | $132.2M | $187.5M | $153.6M |
| Cash and short-term investments | $69.1M | $103.9M | $140.7M | $179.6M | $153.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40M | $9.64M | $6.14M | $10.6M | $1.58M |
| Cost of revenue | $6.34M | $7.57M | $6.1M | $6.72M | $1.37M |
| Gross profit | $33.7M | $2.07M | $40K | $3.87M | $210K |
| Research and development expenses | $17.4M | $18.9M | $30.1M | $28.3M | $10.6M |
| Selling, general and administrative expenses | $10.6M | $34M | $32.6M | $29.3M | $16.3M |
| Other expenses | $17.9M | -$-8.68M | -$-7.53M | -$-8.47M | -$-4.76M |
| Operating expenses | $45.9M | $44.2M | $55.2M | $49.1M | $22.1M |
| Cost and expenses | $52.2M | $51.8M | $61.3M | $55.9M | $23.5M |
| Interest income | $3.54M | $5.31M | $6.79M | $3.03M | $80K |
| Interest expense | $320K | $540K | $610K | $340K | $290K |
| Depreciation and amortization | $2.8M | $2.85M | $2.38M | $1.27M | $560K |
| Ebitda | -$-12.73M | -$-33.32M | -$-54.95M | -$-20.05M | -$-24.76M |
| Operating income | -$-12.16M | -$-42.12M | -$-55.11M | -$-45.25M | -$-21.92M |
| Total other income/expenses, net | -$-3.69M | $5.41M | -$-2.83M | $23.6M | -$-3.68M |
| Income before tax | -$-15.85M | -$-36.71M | -$-57.94M | -$-21.66M | -$-25.61M |
| Income tax expense | $0.00 | -$-60K | $130K | $0.00 | $0.00 |
| Net income | -$-15.85M | -$-36.65M | -$-58.07M | -$-21.66M | -$-25.61M |
| Weighted average shares outstanding | $6.43M | $6.4M | $6.4M | $6.03M | $5.13M |
| Weighted average diluted shares outstanding | $6.43M | $6.4M | $6.4M | $6.03M | $5.13M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $69.1M | $103.9M | $140.7M | $179.6M | $153.4M |
| Net receivables | $4.89M | $4.6M | $2.08M | $11.1M | $5.32M |
| Inventory | $6.59M | $23.3M | $23.7M | $16.6M | $6.55M |
| Total current assets | $81.4M | $132.1M | $166.5M | $207.3M | $165.2M |
| Property, plant and equipment, net | $7.11M | $9.4M | $11.9M | $8.93M | $1.8M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $15.3M | $0.00 |
| Total non-current assets | $20.4M | $9.4M | $11.9M | $24.2M | $1.8M |
| Total assets | $101.9M | $141.5M | $178.4M | $231.5M | $167M |
| Accounts payable | $1.98M | $2.35M | $4.88M | $5.74M | $830K |
| Short-term debt | $2.04M | $1M | $920K | $850K | $550K |
| Deferred revenue | $940K | $5.12M | $5.09M | $5.04M | $2.29M |
| Total current liabilities | $10.3M | $14.2M | $14.3M | $15.2M | $6.71M |
| Long-term debt | $540K | $2.23M | $4.77M | $6.08M | $460K |
| Deferred revenue, non-current | $0.00 | $22.9M | $22.7M | $22.3M | $0.00 |
| Total non-current liabilities | $8.43M | $24.1M | $26.6M | $26.5M | $1.06M |
| Capital lease obligations | $1.56M | $1.12M | $2.39M | $3.04M | $230K |
| Total liabilities | $18.8M | $38.4M | $47.7M | $48.8M | $7.76M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-183.14M | -$-166.91M | -$-129.44M | -$-70.51M | -$-49.83M |
| Accumulated other comprehensive income (loss) | $10.1M | $10.9M | $10.2M | $7.08M | $2.52M |
| Total equity | $83.1M | $96.7M | $132.2M | $187.5M | $153.6M |
| Total investments | $47.5M | $62.7M | $116.9M | $179.6M | $40.5M |
| Total debt | $1.56M | $3.23M | $5.69M | $6.92M | $1.02M |
| Net debt | -$-20.04M | -$-37.98M | -$-18.12M | -$-8.27M | -$-111.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-15.85M | -$-36.65M | -$-58.07M | -$-21.66M | -$-25.61M |
| Depreciation and amortization | $2.8M | $2.85M | $2.38M | $1.27M | $560K |
| Stock-based compensation | $670K | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-24.05M | -$-3.53M | $390K | $9.47M | -$-6.81M |
| Accounts receivable | -$-390K | -$-2.81M | $10.3M | -$-6.49M | -$-7.12M |
| Inventory | $3.16M | $600K | -$-9.36M | -$-9.57M | -$-2.61M |
| Accounts payable | -$-380K | -$-2.56M | -$-930K | $4.93M | $160K |
| Net cash provided by operating activities | -$-32.88M | -$-33.71M | -$-42.45M | -$-24.51M | -$-26.01M |
| Investments in property, plant and equipment | -$-140K | -$-510K | -$-3.89M | -$-4.41M | -$-770K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $13.9M | $50.8M | $49.4M | -$-297.7M | -$-41.22M |
| Common stock issued | $30K | $0.00 | $0.00 | $50.1M | $174.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $0.00 | -$-1.56M | -$-1.13M | $49.9M | $178.3M |
| Net change in cash | -$-19.57M | $17.2M | $7.94M | -$-110.16M | $107M |
| Cash at end of period | $21.6M | $41.2M | $23.8M | $15.2M | $112.9M |
| Operating cash flow | -$-32.88M | -$-33.71M | -$-42.45M | -$-24.51M | -$-26.01M |
| Capital expenditure | -$-140K | -$-510K | -$-3.89M | -$-4.41M | -$-770K |
| Free cash flow | -$-33.01M | -$-34.22M | -$-46.34M | -$-28.92M | -$-26.79M |
Line items
Line items
Line items
About Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.
- CEO
- Elazar Sonnenschein
- Employees
- 63
- Beta
- 0.38
Explore
Frequently asked questions
What is the intrinsic value of Pulsenmore Ltd. Ordinary Shares (PLSM)?
Pulsenmore Ltd. Ordinary Shares (PLSM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PLSM undervalued?
PLSM trades at a price of $1.29 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.